BIOMAT Database Logo BIOMAT Database Logo

Development and testing of new hypoxic cell radiosensitizers. 1979

B F Kimler, and T McDonald, and C C Cheng, and E G Podrebarac, and C M Mansfield

Several new electron-affinic compounds have been shown to possess radiosensitizing ability in hypoxic mammalian cells. The correlation between chemical structure and biological activity can aid in the design and synthesis of new agents with potentially greater hypoxic cell radiosensitizing ability.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008795 Metronidazole A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS. 2-Methyl-5-nitroimidazole-1-ethanol,Bayer 5360,Clont,Danizol,Flagyl,Gineflavir,Metric,MetroGel,Metrodzhil,Metrogyl,Metronidazole Hydrochloride,Metronidazole Monohydrochloride,Metronidazole Phosphate,Metronidazole Phosphoester,Satric,Trichazol,Trichopol,Trivazol,Vagilen,2 Methyl 5 nitroimidazole 1 ethanol
D008920 Misonidazole A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic. Ro 07-0582,Ro 7-0582,alpha-(Methoxymethyl)-2-nitro-1H-imidazole-1-ethanol,Ro 07 0582,Ro 070582,Ro 7 0582,Ro 70582
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D011838 Radiation-Sensitizing Agents Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. Radiation Sensitizer,Radiosensitizing Agent,Radiosensitizing Agents,Agents, Radiation-Sensitizing,Radiation Sensitizers,Radiation Sensitizing Agents,Radiation-Sensitizing Drugs,Radiation-Sensitizing Effect,Radiation-Sensitizing Effects,Radiosensitizing Drugs,Radiosensitizing Effect,Radiosensitizing Effects,Agent, Radiosensitizing,Agents, Radiation Sensitizing,Agents, Radiosensitizing,Drugs, Radiation-Sensitizing,Drugs, Radiosensitizing,Effect, Radiation-Sensitizing,Effect, Radiosensitizing,Effects, Radiation-Sensitizing,Effects, Radiosensitizing,Radiation Sensitizing Drugs,Radiation Sensitizing Effect,Radiation Sensitizing Effects,Sensitizer, Radiation,Sensitizers, Radiation,Sensitizing Agents, Radiation
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004307 Dose-Response Relationship, Radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation. Dose Response Relationship, Radiation,Dose-Response Relationships, Radiation,Radiation Dose-Response Relationship,Radiation Dose-Response Relationships,Relationship, Radiation Dose-Response,Relationships, Radiation Dose-Response
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster

Related Publications

B F Kimler, and T McDonald, and C C Cheng, and E G Podrebarac, and C M Mansfield
Testing of hypoxic cell radiosensitizers in vivo.
January 1980, Cancer clinical trials,
B F Kimler, and T McDonald, and C C Cheng, and E G Podrebarac, and C M Mansfield
Testing of hypoxic cell radiosensitizers in vivo.
June 1978, The British journal of cancer. Supplement,
B F Kimler, and T McDonald, and C C Cheng, and E G Podrebarac, and C M Mansfield
Hypoxic cell radiosensitizers.
January 1978, Strahlentherapie. Sonderbande,
B F Kimler, and T McDonald, and C C Cheng, and E G Podrebarac, and C M Mansfield
The search for new hypoxic cell radiosensitizers.
August 1980, Journal of the National Medical Association,
B F Kimler, and T McDonald, and C C Cheng, and E G Podrebarac, and C M Mansfield
Hypoxic cell radiosensitizers: expectations and progress in drug development.
February 1985, International journal of radiation oncology, biology, physics,
B F Kimler, and T McDonald, and C C Cheng, and E G Podrebarac, and C M Mansfield
Editorial: Hypoxic cell radiosensitizers.
June 1976, The New England journal of medicine,
B F Kimler, and T McDonald, and C C Cheng, and E G Podrebarac, and C M Mansfield
Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.
March 1979, British journal of cancer,
B F Kimler, and T McDonald, and C C Cheng, and E G Podrebarac, and C M Mansfield
The rationale for the development of improved hypoxic cell radiosensitizers.
June 1978, The British journal of cancer. Supplement,
B F Kimler, and T McDonald, and C C Cheng, and E G Podrebarac, and C M Mansfield
Hypoxic cell radiosensitizers--present and future.
June 1981, International journal of radiation oncology, biology, physics,
B F Kimler, and T McDonald, and C C Cheng, and E G Podrebarac, and C M Mansfield
Hypoxic cell radiosensitizers: illusion or elusion?
September 1988, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!